Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 13/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | PADI1 | Q9ULC6 | 2/20 | 0.44 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.44 |
| ▸ | PADI2 | Q9Y2J8 | 2/20 | 0.44 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.44 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1310656 | 0.90 | ACE (0.48) | CA1KMT2A | |
| SCHEMBL1310658 | 0.90 | ACE (0.48) | CA1KMT2A | |
| SCHEMBL7380348 | 0.86 | PIN1 (0.47) | HPGDSROCK2ROCK1 | |
| SCHEMBL24433825 | 0.84 | PSMB5 (0.41) | KMT2A | |
| SCHEMBL10522885 | 0.81 | ACE (0.52) | CA1KMT2A | |
| SCHEMBL11273089 | 0.81 | CA2 (0.52) | CA1 | |
| SCHEMBL11273085 | 0.81 | CA2 (0.52) | CA1 | |
| SCHEMBL27506310 | 0.81 | CTSL (0.51) | — | |
| SCHEMBL7281103 | 0.81 | PARP1 (0.50) | — | |
| SCHEMBL12459907 | 0.80 | HPGDS (0.39) | HPGDSCA1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | HPGDS 2859/4885PDE4A 3023/4885PDE4B 3530/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | HPGDS 3019/4885PDE4A 3669/4885PDE4B 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.